FDA Opts For Education Over Registries in Proposed Opioids REMS
This article was originally published in The Pink Sheet Daily
Executive Summary
Registries could have adverse impact on patient access, notes Bob Rappaport, director of CDER's Division of Anesthesia and Analgesia Products.